Adverum Biotechnologies (NASDAQ:ADVM) Earns Buy Rating from HC Wainwright

Adverum Biotechnologies (NASDAQ:ADVM)‘s stock had its “buy” rating reissued by stock analysts at HC Wainwright in a research note issued to investors on Thursday,Benzinga reports. They presently have a $30.00 price objective on the biotechnology company’s stock. HC Wainwright also issued estimates for Adverum Biotechnologies’ Q3 2025 earnings at ($1.19) EPS and Q4 2025 earnings at ($1.17) EPS.

Several other research analysts have also recently issued reports on the stock. Chardan Capital lowered their target price on shares of Adverum Biotechnologies from $40.00 to $33.00 and set a “buy” rating for the company in a report on Thursday, April 17th. Royal Bank of Canada decreased their price target on shares of Adverum Biotechnologies from $10.00 to $5.00 and set a “sector perform” rating for the company in a research note on Wednesday, April 16th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat, Adverum Biotechnologies presently has a consensus rating of “Moderate Buy” and a consensus price target of $26.40.

Adverum Biotechnologies Trading Up 3.4%

Shares of Adverum Biotechnologies stock opened at $2.12 on Thursday. The company has a fifty day simple moving average of $3.64 and a 200-day simple moving average of $4.70. Adverum Biotechnologies has a 12-month low of $1.78 and a 12-month high of $10.14. The stock has a market cap of $44.29 million, a price-to-earnings ratio of -0.35 and a beta of 1.03.

Adverum Biotechnologies (NASDAQ:ADVM) last issued its earnings results on Tuesday, April 15th. The biotechnology company reported ($1.96) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.34) by ($0.62). On average, analysts forecast that Adverum Biotechnologies will post -4.92 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, major shareholder Braden Michael Leonard purchased 30,600 shares of the business’s stock in a transaction dated Thursday, March 20th. The stock was acquired at an average price of $5.61 per share, for a total transaction of $171,666.00. Following the acquisition, the insider now directly owns 2,722,761 shares of the company’s stock, valued at $15,274,689.21. This trade represents a 1.14% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In the last quarter, insiders bought 198,123 shares of company stock worth $863,040 and sold 13,010 shares worth $26,020. 4.20% of the stock is owned by insiders.

Hedge Funds Weigh In On Adverum Biotechnologies

A number of large investors have recently made changes to their positions in ADVM. Regeneron Pharmaceuticals Inc. acquired a new stake in Adverum Biotechnologies in the 4th quarter valued at about $845,000. Barclays PLC boosted its stake in shares of Adverum Biotechnologies by 125.8% during the 3rd quarter. Barclays PLC now owns 35,832 shares of the biotechnology company’s stock worth $252,000 after purchasing an additional 19,965 shares during the last quarter. Marshall Wace LLP boosted its stake in shares of Adverum Biotechnologies by 128.5% during the 4th quarter. Marshall Wace LLP now owns 98,027 shares of the biotechnology company’s stock worth $458,000 after purchasing an additional 55,130 shares during the last quarter. Renaissance Technologies LLC boosted its stake in shares of Adverum Biotechnologies by 249.6% during the 4th quarter. Renaissance Technologies LLC now owns 129,605 shares of the biotechnology company’s stock worth $605,000 after purchasing an additional 92,533 shares during the last quarter. Finally, Geode Capital Management LLC boosted its stake in shares of Adverum Biotechnologies by 0.8% during the 4th quarter. Geode Capital Management LLC now owns 442,490 shares of the biotechnology company’s stock worth $2,067,000 after purchasing an additional 3,434 shares during the last quarter. Hedge funds and other institutional investors own 48.17% of the company’s stock.

Adverum Biotechnologies Company Profile

Adverum Biotechnologies, Inc, a clinical-stage company, develops gene therapy product candidates to treat ocular diseases. Its lead product candidate is ixoberogene soroparvovec (ADVM-022), a single intravitreal injection gene therapy candidate used for the treatment of patients with wet age-related macular degeneration and diabetic macular edema which is in phase 2 clinical trials.